One example would be Navitoclax (ABT‐263), which exerts its senolytic activity by targeting Bcl‐2 anti‐apoptotic proteins, and when administered in combination with gemcitabine, it was demonstrated to kill gemcitabine‐resistant and senescent‐like pancreatic cancer cells [50]. This evidence concerns the gene BCL2 and familial pancreatic carcinoma.